Non-Ischemic Causes of Troponin Elevation: Getting It Right. March 28, 2015

Similar documents
REVISED MI DEFINITIONS IMPLICATIONS FOR CLINICAL TRIALS. Maarten L Simoons Thoraxcenter - Erasmus MC Rotterdam - The Netherlands

The Universal Definition of Myocardial Infarction 3 rd revision, 2012

Tests I Wish You Had Not Ordered. Scott Girard D.O. FACOI Hospitalist

TROPONINS HAVE THEY CHANGED YOUR

Richard Grocott Mason

Essam Mahfouz, MD. Professor of Cardiology, Mansoura University

Acute Coronary Syndromes: Challenges to Management. Claire Williams November 2017

Measuring Natriuretic Peptides in Acute Coronary Syndromes

TROPONIN POSITIVE 2/20/2015 WHAT DOES IT MEAN? When should a troponin level be obtained?

Topic. Updates on Definition of Myocardial Infarction

HIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD

New universal definition of myocardial infarction

Chest pain management. Ruvin Gabriel and Niels van Pelt August 2011

WHI Form Report of Cardiovascular Outcome Ver (For items 1-11, each question specifies mark one or mark all that apply.

Peri-operative Troponin Measurements - Pathophysiology and Prognosis

Biomarkers in cardiovascular disease. Felix J. Rogers, DO, FACOI April 29, 2018

UPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME. DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

Myocardial injury, necrosis and infarction

Ischemic Heart Disease

(For items 1-12, each question specifies mark one or mark all that apply.)

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases

Takotsubo cardiomyopathy. Joseph L. Blackshear, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Florida

About OMICS International

Cardiovascular emergencies. 05/March/2014 László Rudas Szeged

EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE

TYPE II MI. KC ACDIS LOCAL CHAPTER March 8, 2016

Practitioner Education Course

Supplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1.

Acute Coronary Syndrome

My Patient Needs a Stress Test

RECOMMENDATIONS FOR USE OF POINT-OF- CARE TROPONIN ASSAYS IN ASSESSMENT OF ACUTE CORONARY SYNDROME

When Should I Order a Stress Test or an Echocardiogram

Acute Coronary Syndrome. Sonny Achtchi, DO

BEDSIDE ASSESSMENT OF PATIENTS WITH STEMI

Detailed Order Request Checklists for Cardiology

Post Operative Troponin Leak: David Smyth Christchurch New Zealand

The use of Cardiac CT and MRI in Clinical Practice

Perioperative Infarcts: Epidemiology, predictors and post-op monitoring

HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM

High-Sensitivity Troponin and the Diagnosis of NSTEMI in Hospitalized Medical Patients

Diagnosis and Management of Acute Myocardial Infarction

DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN

Cardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray

Troponin = 35. Objectives. Low Risk Chest Pain. Does this patient have ACS? Does this patient have ACS? Objectives

Chapter 21: Clinical Exercise Testing Procedures

Supplementary Table 1. Details of the components of the primary composite endpoint

Current Utilities of Cardiac Biomarker Testing at POC. June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN

Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D.

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology

Perioperative Myocardial Infarction

Myocardial Infarction In Dr.Yahya Kiwan

An update on the management of UA / NSTEMI. Michael H. Crawford, MD

High Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr.

Cardiac Pathology & Rehabilitation

2015 Preliminary Agenda

Takotsubo Cardiomyopathy: Pathophysiology and Assessment

A Diagnostic Dilemma saved by sound

The presenter does not have any potential conflicts of interest to disclose

A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD

Women and Vascular Disease

The importance of follow-up after a cardiac event: CARDIAC REHABILITATION. Dr. Guy Letcher

Management of Acute Myocardial Infarction

7. Echocardiography Appropriate Use Criteria (by Indication)

BIOCHEMICAL INVESTIGATIONS IN THE DIAGNOSTICS OF CARDIOVASCULAR DISORDERS. As. MARUSHCHAK M.I.

Acute coronary syndrome. Dr LM Murray Chemical Pathology Block SA

Acute heart failure in a patient with lower urinary tract infection Case report of an infection-induced Reverse Takotsubo syndrome

What is hypertension?

ECG Workshop. Nezar Amir

Supplementary webappendix

Defining rise and fall of cardiac troponin values

Coral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure.

Takotsubo syndrome. Ευτυχία Σμπαρούνη, FACC, FESC

10/8/2018. Lecture 9. Cardiovascular Health. Lecture Heart 2. Cardiovascular Health 3. Stroke 4. Contributing Factor

10. Definition of cardiovascular disease 10.1 Nosologic definitions Acute myocardial infarction: myocardial cell death due to prolonged ischaemia 62.

High-Sensitivity Cardiac Troponin in Suspected ACS

Welcome! To submit questions during the presentation: or Text:

Cardiovascular Disease

Acute cardiogenic shock with standing-still heart

Results of Ischemic Heart Disease

12 Lead ECG Interpretation

Impact of Chest Pain Protocol Targeting Intermediate Cardiac Risk Patients in an Observation Unit of an Academic Tertiary Care Center

Preliminary Programme

GUIDELINES FOR TROPONIN TESTING: AN EVIDENCE-BASED APPROACH TO DIAGNOSIS AND TREATMENT OF THE ACS PATIENT

What is a myocardial infarction and how do we treat it? Paul Das Consultant Cardiologist North Wales Cardiac Centre Glan Clwyd Hospital

Cardiovascular Disorders. Heart Disorders. Diagnostic Tests for CV Function. Bio 375. Pathophysiology

Objectives. Identify early signs and symptoms of Acute Coronary Syndrome Initiate proper protocol for ACS patient 10/2013 2

Chest Pain in Women ;What is Your Diagnostic Plan? No Need for Noninvasive Test

HEART FAILURE PATIENT MANAGEMENT. To The Power of 2!

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.

Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, MD, FHRS

Heart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output

How will new high sensitive troponins affect the criteria?

CHRONIC CAD DIAGNOSIS

Unit 4 Problems of Cardiac Output and Tissue Perfusion

JMSCR Vol 05 Issue 01 Page January 2017

Yes No Unknown. Major Infection Information

CURRENT STATUS OF STRESS TESTING JOHN HAMATY D.O.

Cardiovascular Diseases and Diabetes

Transcription:

Non-Ischemic Causes of Troponin Elevation: Getting It Right March 28, 2015

WHY discuss this...? Misconceptions about meaning of elevated troponin Validation of troponin when utilized properly Prognostic value (?) in certain circumstances Improper use or interpretation can be a very co$$$tly mistake for the hospital Troponin DOES matter

Types of Myocardial Necrosis Events

From: ACCF 2012 Expert Consensus Document on Practical Clinical Considerations in the Interpretation of Troponin Elevations: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents

Public Policy Implications Of The Adjustment Of The Mi Definition Revision of the definition of MI has a number of implications for individuals as well as for society at large. A tentative or final diagnosis is the basis for advice about further diagnostic testing, lifestyle changes, treatment and prognosis for the patient. The aggregate of patients with a particular diagnosis is the basis for health care planning and policy and resource allocation. One of the goals of good clinical practice is to reach a definitive and specific diagnosis, which is supported by current scientific knowledge. The approach to the definition of MI outlined in this document meets this goal. In general, the conceptual meaning of the term myocardial infarction has not changed, although new, sensitive diagnostic methods have been developed to diagnose this entity. Thus, the diagnosis of acute MI is a clinical diagnosis based on patient symptoms, ECG changes, and highly sensitive biochemical markers, as well as information gleaned from various imaging techniques. It is important to characterize the type of MI as well as the extent of the infarct, residual LV function, and the severity of CAD and other risk factors, rather than merely making a diagnosis of MI. The information conveyed about the patient's prognosis and ability to work requires more than just the mere statement that the patient has suffered an MI. The many additional factors just mentioned are also required so that appropriate social, family, and employment decisions can be made. A number of risk scores have been developed to predict the prognosis after MI. The classification of the various other prognostic entities associated with MI should lead to a reconsideration of the clinical coding entities currently employed for patients with the myriad conditions that can lead to myocardial necrosis, with consequent elevation of biomarker values. It should be appreciated that the current modification of the definition of MI may be associated with consequences for the patients and their families in respect of psychological status, life insurance, professional career, as well as driving- and pilots' licenses. The diagnosis is associated also with societal implications as to diagnosis-related coding, hospital reimbursement, public health statistics, sick leave, and disability attestation. In order to meet this challenge, physicians must be adequately informed of the altered The diagnosis is associated also with diagnostic criteria. Educational materials will need to be created and treatment guidelines must be appropriately adapted. Professional societies and healthcare planners should take steps to facilitate the rapid dissemination of the revised definition to physicians, other health care professionals, administrators, and the general public. societal implications as to diagnosisrelated coding, hospital reimbursement, public health statistics, sick leave...

Universal Definition of Myocardial Infarction Detect rise/fall of cardiac biomarker (preferrably troponin) into/from the abnormal range with AT LEAST ONE OF THE FOLLOWING: Classic ischemic chest pain symptoms New ST changes or LBBB Pathologic Q waves Imaging showing new wall motion or new myocardial abnormality Plaque rupture/thrombus on angiography

Another reminder -- Troponin level rises within 4hrs of myocardial injury but stays elevated 7-10d Great diagnostic for recent MI Poor diagnostic for re-infarct (CK-MB better here)

2007 National Academy of Clinical Biochemistry issued guidelines state: In the presence of a clinical history suggesting of acute coronary syndrome, the following is considered indicative of myocardial necrosis consistent with myocardial infarction: Maximal concentration of cardiac troponin exceeding the 99th percentile of values (with optimal precision defined by total CV <10%) for a reference group on at least one occasion during the first 24 hours after the clinical event. In order to meet this definition at NMMC, troponin elevation would need to exceed 0.34ng/ml (NMMC ULN currently 0.120ng/ml)

Other Cardiac Causes of Troponinemia Chest/Cardiac Trauma Cardiac Surgery/Recent Angioplasty Cardioversion Acute on Chronic Heart Failure Aortic Dissection Tachyarrhythmias Bradyarrhtyhmia/Heart Block Endocarditis Pericarditis/Myocarditis Non-Cardiac Causes of Troponinemia Pulmonary Embolus Pulmonary Hypertension Severe COPD/Asthma Attack Renal Failure Stroke and Subarachnoid Bleed Sepsis Burns Extreme Exertion Cardiotoxic Drugs Severe Aortic Valve Disease

Pulmonary Embolus 2007 meta-analysis: median rate of troponin elevation was 39% Troponin elevation associations in PE: short-term (<30 day) all-cause mortality highly associated with fatal PE non-fatal complications Pulm vascular obstruction - vasoconstriction - sudden PVR and PA pressure increase - RV afterload RV dysfunction = increased mortality in PE

Chronic Kidney Disease Troponin elevation likely not caused solely by reduced renal clearance (Intact troponin = large molecules) Elimination of Trop I similar in normal renal fxn and ESRD Associations of Troponin with CKD: All-cause mortality (RR 2.64) Cardiac Death (RR 2.55) NACB Laboratory Medicine Practice Guidelines: Rely on dynamic change in troponin >20% in 6-9hr range FDA approved Trop T for identifying CKD pts with high mortality risk

Sepsis Myocardial dysfunction common Meta-analysis of 10 sepsis studies - median 62% with troponin elevation 5 studies found significant association btwn troponin + and death Elevated troponin is a potential marker for LV dysfunction Routine troponin testing in sepsis is NOT recommended

Chemotherapy-Associated Cardiotoxicity Expert panel: troponin is the preferred biomarker to detect drug-induced cardiac injury Facts: Trop (+), any level, any time = increased risk of permanent/more severe LV dysfunction Enalapril treatment addition... Trop (-) in pts with early LV dysfunction tend toward better/full LV recovery Known: Useful in detecting toxicity and severity Unknown: Predicting long-term CV mortality

Other Cardiac Causes of Troponinemia Chest/Cardiac Trauma Cardiac Surgery/Recent Angioplasty Cardioversion Acute on Chronic Heart Failure Aortic Dissection Tachyarrhythmias Bradyarrhtyhmia/Heart Block Endocarditis Pericarditis/Myocarditis Non-Cardiac Causes of Troponinemia Pulmonary Embolus Pulmonary Hypertension Severe COPD/Asthma Attack Renal Failure Stroke and Subarachnoid Bleed Sepsis Burns Extreme Exertion Cardiotoxic Drugs Severe Aortic Valve Disease

When troponin was a lousy assay, it was a great test, but now that it s become a great assay, it s getting to be a lousy test

CMS Reimbursement Reductions based on 30day readmission: 2013 = 1% 2014 = 2% 2015 = 3%

Thank You Questions?